Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Unresectable lung malignancy: combination therapy with segmental pulmonary arterial chemoembolization with drug-eluting microspheres and radiofrequency ablation in 17 patients.
Gadaleta CD, Solbiati L, Mattioli V, Rubini G, Fazio V, Goffredo V, Vinciarelli G, Gadaleta-Caldarola G, Canniello E, Armenise F, D'Aluisio L, Gaudiano A, Ranieri G, Goldberg SN. Gadaleta CD, et al. Among authors: rubini g. Radiology. 2013 May;267(2):627-37. doi: 10.1148/radiol.12120198. Epub 2012 Dec 18. Radiology. 2013. PMID: 23249572
A pilot study employing hepatic intra-arterial irinotecan injection of drug-eluting beads as salvage therapy in liver metastatic colorectal cancer patients without extrahepatic involvement: the first southern Italy experience.
Ranieri G, Niccoli Asabella A, Altini C, Fazio V, Caporusso L, Marech I, Vinciarelli G, Macina F, de Ceglia D, Fanelli M, Ammendola M, Rubini G, Gadaleta CD. Ranieri G, et al. Among authors: rubini g. Onco Targets Ther. 2016 Dec 12;9:7527-7535. doi: 10.2147/OTT.S112670. eCollection 2016. Onco Targets Ther. 2016. PMID: 28003766 Free PMC article.
18F-FDG PET/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria.
Niccoli Asabella A, Di Palo A, Altini C, Fanelli M, Ferrari C, Lavelli V, Ranieri G, Gadaleta CD, Rubini G. Niccoli Asabella A, et al. Among authors: rubini g. Hell J Nucl Med. 2018 Sep-Dec;21(3):191-197. doi: 10.1967/s002449910904. Epub 2018 Nov 10. Hell J Nucl Med. 2018. PMID: 30411729 Free article.
Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study.
Ranieri G, Laface C, Laforgia M, De Summa S, Porcelli M, Macina F, Ammendola M, Molinari P, Lauletta G, Di Palo A, Rubini G, Ferrari C, Gadaleta CD. Ranieri G, et al. Among authors: rubini g. Front Oncol. 2020 Nov 3;10:590707. doi: 10.3389/fonc.2020.590707. eCollection 2020. Front Oncol. 2020. PMID: 33224885 Free PMC article.
Corrigendum: Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study.
Ranieri G, Laface C, Laforgia M, De Summa S, Porcelli M, Macina F, Ammendola M, Molinari P, Lauletta G, Di Palo A, Rubini G, Ferrari C, Gadaleta CD. Ranieri G, et al. Among authors: rubini g. Front Oncol. 2021 Feb 5;10:637880. doi: 10.3389/fonc.2020.637880. eCollection 2020. Front Oncol. 2021. PMID: 33614511 Free PMC article.
248 results